Maximizing Your ACO’s Savings Potential: What CFOs Need to Know About LEAD Before the RFA Opens

The most consequential value-based care decision in a decade is happening right now - and most ACO finance teams are not ready for it.

CMS has launched the LEAD (Long-Term Enhanced ACO Design) model, and the clock is running. For CFOs, Chief Strategy Officers, and population health leaders, the question is no longer whether to engage with value-based care. You're already in it. The question is whether your current MSSP participation is still the right vehicle - or whether LEAD represents a fundamentally better financial structure for your organization's next chapter.

This is not a theoretical policy debate. It is a high-stakes financial decision with real consequences for your 2027 performance and beyond. Here's what your team needs to understand before the application window closes.

Why 2027 Is Different From Every Prior VBC Decision

MSSP has been the default track for most ACOs for over a decade. It's familiar. It has an established operational playbook. And for many organizations, it has delivered real savings.

But familiarity is not the same as optimization.

MSSP ACOs that have performed well are now facing a structural problem: benchmark rebasing. Every time your ACO generates savings, CMS adjusts your future benchmark downward. Your performance is being used against you. The better you do, the harder it becomes to generate savings in subsequent years. For CFOs modeling long-term financial sustainability, this is not a minor technical detail - it is a fundamental constraint on your upside.

LEAD addresses this directly. The model's no-rebasing commitment is one of its most significant structural differences. For high-performing ACOs, that single feature changes the long-term financial calculus entirely. But LEAD also introduces a 10-year commitment and two-sided risk requirements that cannot be entered into without serious financial modeling and operational preparation.

That tension - compelling upside, meaningful risk - is exactly why this decision requires more than a policy briefing. It requires a framework, financial projections, and an honest assessment of your organization's current infrastructure.

The Financial Case: What CFOs Are Actually Asking

When your CFO sits down to evaluate LEAD versus MSSP, three questions dominate the conversation.

First: What is the true financial upside and downside of each model?

MSSP's rebasing problem compounds over time. For an ACO that has been in MSSP for several years and consistently generated savings, the benchmark erosion is already significant. LEAD's stable benchmark structure preserves the value of your performance improvements year over year - which means the financial upside for a high-performing ACO grows rather than shrinks.

But LEAD's two-sided risk structure means losses are also real. Before committing, your finance team needs actuarial-grade modeling of your population's cost trajectory, your historical performance variance, and your capacity to absorb downside scenarios. Directional estimates are not sufficient for a 10-year commitment.

Second: What does the Full TIN requirement mean for our financial exposure?

LEAD's Full TIN approach — which attributes all patients under a participating tax identification number - is fundamentally different from MSSP's more selective attribution. This expands your population and your risk surface simultaneously. For some organizations, this is an opportunity to capture more savings from a broader population. For others, it exposes cost centers that have not yet been brought under active management.

Understanding which category your organization falls into requires complete visibility into your attributed population's cost and utilization patterns — not just your high-risk cohort, but every attributed life.

Third: Are we operationally ready for what LEAD demands?

LEAD's CARA specialist integration requirements and population management infrastructure demands are not incremental upgrades to your current MSSP workflow. They represent a step-change in operational complexity. Many ACOs that are financially ready for LEAD are not yet operationally ready. That gap needs to be closed in 2026 - because 2027 will not wait.

The Data Problem That Sits Beneath Both Models

Here is the uncomfortable truth that most ACO technology discussions avoid: the single biggest barrier to success in either LEAD or MSSP is data fragmentation.

You cannot manage what you cannot see. And most ACOs are managing their populations with a partial picture - clinical data from one or two EHRs, claims data that arrives weeks or months late, and almost no visibility into social determinants that drive 30–40% of health outcomes.

This is not a minor inconvenience. It directly affects your financial performance. A 30% reduction in high-cost patient identification lag is achievable with AI-driven risk stratification built on unified data - but only if that unified data actually exists. When it doesn't, high-risk patients enter expensive care settings before your care management team even knows they're deteriorating.

The organizations that perform best in value-based care contracts - whether MSSP or LEAD - share one characteristic: they have unified clinical, claims, pharmacy, and SDOH data in a single longitudinal patient record. That foundation enables proactive intervention rather than reactive damage control.

Innovaccer's Atlas platform manages the full attributed population - not just the top 5% of high-risk patients, but every attributed life across prevention, chronic disease management, and complex care. Built on 400+ pre-built EHR and data connectors and 6,000+ data quality rules, Atlas gives your population health team the complete picture that VBC performance requires. The results are measurable: a 40% improvement in care gap closure rates with unified data, and organizations like PSW achieving a 16.7% drop in SNF utilization and 12% reduction in avoidable ED visits across 400,000+ lives.

Those are not incremental improvements. At scale, they represent millions of dollars in shared savings.

LEAD's Operational Requirements: What Your Team Needs to Build Now

If your organization is seriously evaluating LEAD, the operational preparation needs to start immediately. The 2027 performance period begins before most teams think they need to be ready.

Risk stratification at full population scale. LEAD's Full TIN approach means you are accountable for every attributed patient - not just the ones your care managers already know. Your risk stratification model needs to identify rising-risk patients before they become high-cost patients. Retrospective chart review alone is no longer sufficient. CMS risk model changes require prospective coding, and the same logic applies to your population management strategy: you need to identify and intervene before cost events occur, not after.

Care gap closure at volume. LEAD's quality performance requirements demand systematic, automated care gap identification and outreach — not manual worklists. Orlando Health demonstrated what this looks like at scale: an 86% improvement in patient engagement and $907K in incremental revenue across 350,000 lives by deploying automated population outreach through Atlas. That kind of engagement infrastructure is what LEAD demands.

Specialist integration and CARA workflows. LEAD's CARA specialist integration is one of its most operationally demanding requirements. Your care coordination workflows need to extend beyond primary care into specialty settings - with real-time data sharing, attribution clarity, and performance visibility across the full care continuum. Organizations without this infrastructure will struggle to meet LEAD's requirements, regardless of their financial readiness.

Financial modeling for a 10-year commitment. This is where actuarial intelligence becomes non-negotiable. Humbi, Innovaccer's actuarial intelligence platform, provides access to a 60M+ Medicare member dataset spanning 2011–2024, enabling your finance team to model VBC contract economics with the precision that a decade-long commitment demands. You need to understand your population's cost trajectory, your benchmark position, and your downside scenarios before signing - not after.

Staying in MSSP: When It's Still the Right Answer

Not every ACO should move to LEAD. For some organizations, MSSP remains the right vehicle - at least for now.

If your organization is early in its VBC journey, if your data infrastructure is still being built, or if your attributed population has significant cost volatility that you don't yet fully understand, the two-sided risk and 10-year commitment of LEAD may introduce more financial exposure than your organization can responsibly absorb.

The benchmark rebasing problem is real, but it is manageable for organizations in earlier performance years. And MSSP's operational requirements, while demanding, are more familiar and more forgiving than LEAD's.

The right answer depends on your specific financial position, your population's cost profile, your existing infrastructure, and your organization's risk tolerance. That answer requires data - not instinct.

What is not acceptable is making this decision without a clear framework and verified financial modeling. 64% of healthcare leaders expect revenue gains from value-based care in 2025, according to NAACOS and Innovaccer research. The organizations that capture those gains will be the ones that made deliberate, data-informed decisions about model participation — not the ones that defaulted to the familiar option.

The Window Is Closing - Act With Data, Not Anxiety

The LEAD RFA will open in April sometime. The operational changes required for 2027 performance need to begin in 2026. That timeline is tighter than it appears.

Your team does not need more information. You need a framework, financial projections built on real population data, and an honest assessment of your operational readiness. Those three things are achievable - but not if you wait.

Innovaccer works with ACOs and health systems managing hundreds of thousands of attributed lives across MSSP, and commercial VBC contracts. Our Atlas platform is purpose-built for population health at scale, with pre-built MSSP and ACO measure libraries, AI-driven risk stratification, and automated care gap workflows. Humbi provides the actuarial modeling your CFO needs to evaluate LEAD's financial structure with confidence.

Best in KLAS 2026 for Data and Analytics and CRM.

The decision you make about LEAD and MSSP will shape your organization's financial trajectory for the next decade. Make it with complete data, not partial information.

Schedule a demo and see how Innovaccer helps ACOs model and execute their VBC strategy →